Key result
Carvedilol reduces polymorphonuclear leukocyte ROS generation by ~41% in healthy subjects.
Why the study?
This study was conducted to test whether carvedilol has an antioxidant effect in humans in vivo.
Does carvedilol reduce reactive oxygen species generation and oxidative damage to amino acids in normal subjects?
Does carvedilol reduce reactive oxygen species generation and oxidative damage to amino acids in normal subjects?
Answers are grounded in this paper and cite their sources.
Carvedilol demonstrates in vivo antioxidant effects by reducing reactive oxygen species generation and oxidative damage to amino acids in normal subjects.
Background —The purpose of this study was to test whether carvedilol has an antioxidant effect in humans in vivo. Methods and Results —We administered 3.125 mg of carvedilol twice daily to normal subjects for 1 week. ROS generation by polymorphonuclear leukocytes and mononuclear cells fell from 314±183.43 and 303±116 mV to 185±157 and 189±63 mV ( P <0.025), respectively. m -Tyrosine fell from 4.24±0.99 to 4.03±0.97 ng/mL ( P =0.01), and o -tyrosine fell from 4.59±1.10 to 4.24±0.99 ng/mL ( P =0.004) in the absence of a change in phenylalanine concentrations. Conclusions —We conclude that carvedilol significantly inhibits ROS generation by leukocytes and oxidative conversion of phenylalanine to m - and o -tyrosine.
No takes yet. Share an insight, caveat, or question.
Dandona et al. (2000) studied Normal subjects. Carvedilol vs. Baseline was evaluated on ROS generation by polymorphonuclear leukocytes and mononuclear cells (p=<0.025). Carvedilol administration reduced ROS generation by polymorphonuclear leukocytes from 314 to 185 mV in normal subjects.
Synapse has enriched 10 related papers. Consider them for comparative context: